ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0432

Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis

Javier Federico Flores Trejo1, Joan Manuel Dapeña2, Florencia Micaela Pascual3, Graciela Liliana Ghiglione1, Juan Manuel Bande3, María Alejandra Medina3, José Angel Caracciolo3 and Silvia Beatriz Papasidero3, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Sanatorio Dr Julio Méndez, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 3Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina

Meeting: ACR Convergence 2025

Keywords: Eye Disorders, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that primarily affects synovial joints but may also involve extra-articular organs. Ocular involvement is one of the most common extra-articular manifestations and may result from disease activity or treatment-related complications. The aim of this study was to describe the ophthalmologic manifestations in a cohort of patients with RA and to evaluate their association with sociodemographic and disease-related characteristics.

Methods: A cross-sectional, observational, descriptive and analytical study was conducted. Consecutive patients ≥ 18 years old with RA (2010 ACR/EULAR criteria) were included. Sociodemographic data, disease characteristics, history of ocular involvement and current treatment were recorded. All patients were asked to complete the Ocular Surface Disease Index (OSDI) and underwent a comprehensive ophthalmologic evaluation performed by the same specialist, including tear break-up time (TBUT), Schirmer’s test, slit-lamp biomicroscopy, fundoscopy and intraocular pressure measurement. Descriptive statistics were used to summarize results. Associations between ocular dryness severity and clinical variables were analyzed using Chi-squared and Spearman correlation tests. A p-value ≤ 0.05 was considered statistically significant.

Results: A total of 50 patients were included. Patient’s characteristics are shown in Table 1. Fifty percent reported previous sicca symptoms, with xerophthalmia being the most frequent (46%). Sjögren’s syndrome associated with RA was identified in 6% of patients. The median OSDI score was 8.3 (IQR 4.2–38.0), classifying 40% of patients as having moderate-to-severe ocular dryness. Ophthalmologic examination revealed xerophthalmia in 94% of cases (78% mild, 12% moderate, 4% severe). Cataracts were observed in 46% of patients, with nuclear cataracts accounting for 32%. All ophthalmologic evaluations are detailed in Table 2. Patients with moderate-to-severe dryness based on OSDI had significantly higher disease activity by DAS28 (p = 0.025) and SDAI (p = 0.018).

Conclusion: In our cohort of RA patients, the most frequent ocular manifestation was xerophthalmia, which was mild in 78% of cases. Cataracts were present in 46% of patients, with the nuclear subtype being the most common. Moderate-to-severe dry eye symptoms were associated with higher disease activity. These results highlight the importance of identifying ocular symptoms in RA and suggest that ocular surface involvement may reflect a higher systemic inflammatory burden.

Supporting image 1

Supporting image 2


Disclosures: J. Flores Trejo: None; J. Dapeña: None; F. Pascual: None; G. Ghiglione: None; J. Bande: None; M. Medina: None; J. Caracciolo: None; S. Papasidero: None.

To cite this abstract in AMA style:

Flores Trejo J, Dapeña J, Pascual F, Ghiglione G, Bande J, Medina M, Caracciolo J, Papasidero S. Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/frequency-and-characteristics-of-ophthalmologic-involvement-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-characteristics-of-ophthalmologic-involvement-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology